ERBB2 and neoplasm: In contrast, HER2−/HSFs+ BT483 cells grew more slowly as xenografts, but lapatinib administration resulted in significant and sustained inhibition of tumor growth, which was apparent within 12 days of the onset of treatment (Fig. 5b).